Please assess the completion status of the following clinical trial:

Trial Title: Effective Treatment for Prescription Opioid Abuse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* For inclusion in the proposed studies, subjects must be \> 18 years old and in good health. Subjects must meet DSM-IV criteria for opioid dependence and FDA qualification criteria for buprenorphine treatment, including a history of opioid dependence and significant current opioid use (i.e., opioid-positive urines). Subjects must also be seeking or willing to accept opioid detoxification.~Exclusion Criteria:~* Because the primary focus of the proposed research is to develop an efficacious intervention for prescription opioid abuse that employs a buprenorphine taper and subsequent naltrexone maintenance, individuals who require ongoing opioid therapy for pain or other chronic medical conditions will be excluded from participating.~* Individuals with evidence of an active psychiatric disorder that may interfere with consent or participation in the research (e.g., psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g., cardiovascular disease) or who are pregnant or nursing will be excluded from participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1-week buprenorphine taper (Type: EXPERIMENTAL): 1-week buprenorphine taper + behavioral therapy + urine toxicology
- 2-week buprenorphine taper (Type: EXPERIMENTAL): 2-week buprenorphine taper + behavioral therapy + urine toxicology
- 4-week buprenorphine taper (Type: EXPERIMENTAL): 4-week buprenorphine taper + behavioral therapy + urine toxicology

Based on this trial design, predict the completion outcome and termination type (if applicable).